Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study

Disease State: Waldenström's macroglobulinemia

BGB-11417-101 (NCT04277637) is a Phase 1a/1b, open-label, dose-escalation and expansion trial of sonrotoclax in patients with mature B-cell malignancies.

Reading
6 Dec 2024

ASPEN (NCT03053440) is a Phase 3, open-label, randomized trial comparing zanubrutinib with ibrutinib in activating MYD88 mutated (MYD88MUT) Waldenström’s macroglobulinemia (WM) patients. In an additional cohort, the efficacy and safety of zanubrutinib in MYD88 wild-type (MYD88WT) WM patients were evaluated.

Reading
6 Dec 2024

Zanubrutinib is a next-generation Bruton’s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability.

6 Dec 2024

Sonrotoclax is an investigational potent and selective inhibitor of BCL2.

6 Dec 2024